1. Samocha, K. E. et al. Regional missense constraint improves variant deleteriousness prediction. Preprint at https://www.bioRxiv.org/content/10.1101/148353v1 (2017).

2. Marouli, E. et al. Rare and low-frequency coding variants alter human adult height. Nature 542, 186–190 (2017).

3. Flannick, J. et al. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. Nature 570, 71–76 (2019).

4. Timpson, N. J., Greenwood, C. M. T., Soranzo, N., Lawson, D. J. & Richards, J. B. Genetic architecture: the shape of the genetic contribution to human traits and disease. Nat. Rev. Genet. 19, 110–124 (2018).

5. Zuk, O. et al. Searching for missing heritability: designing rare variant association studies. Proc. Natl Acad. Sci. USA 111, E455–E464 (2014).

6. Xue, Y. et al. Enrichment of low-frequency functional variants revealed by whole-genome sequencing of multiple isolated European populations. Nat. Commun. 8, 15927 (2017).

7. Southam, L. et al. Whole genome sequencing and imputation in isolated populations identify genetic associations with medically-relevant complex traits. Nat. Commun. 8, 15606 (2017).

8. Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747–753 (2009).

9. Jakkula, E. et al. The genome-wide patterns of variation expose significant substructure in a founder population. Am. J. Hum. Genet. 83, 787–794 (2008).

10. Polvi, A. et al. The Finnish disease heritage database (FinDis) update—a database for the genes mutated in the Finnish disease heritage brought to the next-generation sequencing era. Hum. Mutat. 34, 1458–1466 (2013).

11. Manning, A. et al. A low-frequency inactivating AKT2 variant enriched in the Finnish population is associated with fasting insulin levels and type 2 diabetes risk. Diabetes 66, 2019–2032 (2017).

12. Lim, E. T. et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. PLoS Genet. 10, e1004494 (2014).

13. Service, S. K. et al. Re-sequencing expands our understanding of the phenotypic impact of variants at GWAS loci. PLoS Genet. 10, e1004147 (2014).

14. Würtz, P. et al. Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technologies. Am. J. Epidemiol. 186, 1084–1096 (2017).

15. Laakso, M. et al. The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases. J. Lipid Res. 58, 481–493 (2017).

16. Borodulin, K. et al. Forty-year trends in cardiovascular risk factors in Finland. Eur. J. Public Health 25, 539–546 (2015).

17. Abraham, G. et al. Genomic prediction of coronary heart disease. Eur. Heart J. 37, 3267–3278 (2016).

18. Sabatti, C. et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat. Genet. 41, 35–46 (2009).

19. Pulizzi, N. et al. Interaction between prenatal growth and high-risk genotypes in the development of type 2 diabetes. Diabetologia 52, 825–829 (2009).

20. Fagerberg, L. et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell. Proteomics 13, 397–406 (2014).

21. Corsetti, J. P. et al. Thrombospondin-4 polymorphism (A387P) predicts cardiovascular risk in postinfarction patients with high HDL cholesterol and C-reactive protein levels. Thromb. Haemost. 106, 1170–1178 (2011).

22. Zhang, X. J. et al. Association between single nucleotide polymorphisms in thrombospondins genes and coronary artery disease: a meta-analysis. Thromb. Res. 136, 45–51 (2015).

23. Beygo, J. et al. New insights into the imprinted MEG8-DMR in 14q32 and clinical and molecular description of novel patients with Temple syndrome. Eur. J. Hum. Genet. 25, 935–945 (2017).

24. Wallace, C. et al. The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nat. Genet. 42, 68–71 (2010).

25. Day, F. R. et al. Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nat. Genet. 49, 834–841 (2017).

26. Perry, J. R. et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature 514, 92–97 (2014).

27. Cleaton, M. A. et al. Fetus-derived DLK1 is required for maternal metabolic adaptations to pregnancy and is associated with fetal growth restriction. Nat. Genet. 48, 1473–1480 (2016).

28. Chaves, J. A. et al. Genomic variation at the tips of the adaptive radiation of Darwin’s finches. Mol. Ecol. 25, 5282–5295 (2016).

29. Surakka, I. et al. The impact of low-frequency and rare variants on lipid levels. Nat. Genet. 47, 589–597 (2015).

30. Ding, Y. et al. Plasma glycine and risk of acute myocardial infarction in patients with suspected stable angina pectoris. J. Am. Heart Assoc. 5, e002621 (2015).

31. Wittemans, L. B. L. et al. Assessing the causal association of glycine with risk of cardio-metabolic diseases. Nat. Commun. 10, 1060 (2019).

32. Perry, R. J. et al. Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome. Nature 534, 213–217 (2016).

33. Tabbassum, R. et al. Genetics of human plasma lipidome: understanding lipid metabolism and its link to diseases beyond traditional lipids. Preprint at https://www.biorxiv.org/content/10.1101/457960v1 (2018).

34. Casanova, M. L. et al. Exocrine pancreatic disorders in transsgenic mice expressing human keratin 8. J. Clin. Invest. 103, 1587–1595 (1999).

35. Surendran, P. et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat. Genet. 48, 1151–1161 (2016).

36. Liu, C. et al. Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. Nat. Genet. 48, 1162–1170 (2016).

37. Palmer, C. & Pe’er, I. Statistical correction of the winner’s curse explains replication variability in quantitative trait genome-wide association studies. PLoS Genet. 13, e1006916 (2017).

38. Norio, R. Finnish Disease Heritage I: characteristics, causes, background. Hum. Genet. 112, 441–456 (2003).

39. Service, S. et al. Magnitude and distribution of linkage disequilibrium in population isolates and implications for genome-wide association studies. Nat. Genet. 38, 556–560 (2006).

40. Chiang, C. W. K. et al. Genomic history of the Sardinian population. Nat. Genet. 50, 1426–1434 (2018).

41. Rivas, M. A. et al. Insights into the genetic epidemiology of Crohn’s and rare diseases in the Ashkenazi Jewish population. PLoS Genet. 14, e1007329 (2018).

42. Bastarache, L. et al. Phenotype risk scores identify patients with unrecognized Mendelian disease patterns. Science 359, 1233–1239 (2018).

43. Niemi, M. E. K. et al. Common genetic variants contribute to risk of rare severe neurodevelopmental disorders. Nature 562, 268–271 (2018).

44. Surakka, I. The rate of false polymorphisms introduced when imputing genotypes from global imputation panels. Preprint at https://www.biorxiv.org/content/10.1101/080770v1 (2016).

45. Collins, F. S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793–795 (2015).

46. Stancáková, A. et al. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 58, 1212–1221 (2009).

47. Borodulin, K. et al. Cohort profile: the National FINRISK Study. Int. J. Epidemiol. 47, 696–696i (2017).

48. Wu, J. et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am. J. Hypertens. 18, 935–942 (2005).

49. Tobin, M. D., Sheehan, N. A., Scurrah, K. J. & Burton, P. R. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. Stat. Med. 24, 2911–2935 (2005).

50. Liu, D. J. et al. Exome-wide association study of plasma lipids in >300,000 individuals. Nat. Genet. 49, 1758–1766 (2017).

51. Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499–502 (1972).

52. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).

53. Jun, G. et al. Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data. Am. J. Hum. Genet. 91, 839–848 (2012).

54. Tan, A., Abecasis, G. R. & Kang, H. M. Unified representation of genetic variants. Bioinformatics 31, 2202–2204 (2015).

55. Davis, J. P. et al. Common, low-frequency, and rare genetic variants associated with lipoprotein subclasses and triglyceride measures in Finnish men from the METSIM study. PLoS Genet. 13, e1007079 (2017).

56. Das, S. et al. Next-generation genotype imputation service and methods. Nat. Genet. 48, 1284–1287 (2016).

57. The Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48, 1279–1283 (2016).

58. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).

59. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249 (2010).

60. Chun, S. & Fay, J. C. Identification of deleterious mutations within three human genomes. Genome Res. 19, 1553–1561 (2009).

61. Schwarz, J. M., Cooper, D. N., Schuelke, M. & Seelow, D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat. Methods 11, 361–362 (2014).

62. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073–1081 (2009).

63. Kang, H. M. et al. Variance component model to account for sample structure in genome-wide association studies. Nat. Genet. 42, 348–354 (2010).

64. Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005–D1012 (2019).

65. Kettunen, J. et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat. Commun. 7, 11122 (2016).

66. Kettunen, J. et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet. 44, 269–276 (2012).

67. Teslovich, T. M. et al. Identification of seven novel loci associated with amino acid levels using single-variant and gene-based tests in 8545 Finnish men from the METSIM study. Hum. Mol. Genet. 27, 1664–1674 (2018).

68. Inouye, M. et al. Novel loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet. 8, e1002907 (2012).

69. Lee, S. et al. Optimal unified approach for rare-variant association testing with application to small-sample case–control whole-exome sequencing studies. Am. J. Hum. Genet. 91, 224–237 (2012).

70. Peterson, C. B., Bogomolov, M., Benjamini, Y. & Sabatti, C. Many phenotypes without many false discoveries: error controlling strategies for multitrait association studies. Genet. Epidemiol. 40, 45–56 (2016).

71. Loh, P. R. et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat. Genet. 48, 1443–1448 (2016).

72. Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).

73. Manichaikul, A. et al. Robust relationship inference in genome-wide association studies. Bioinformatics 26, 2867–2873 (2010).

74. Lawson, D. J., Hellenthal, G., Myers, S. & Falush, D. Inference of population structure using dense haplotype data. PLoS Genet. 8, e1002453 (2012).

75. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).